Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxylanthanum Carbonate in CKD Patients on Dialysis
NCT06218290Phase 2Completed
- Sponsor
- Unicycive Therapeutics
- Start
- Dec 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxylanthanum carbonate in hyperphosphatemia, sponsored by Unicycive Therapeutics. Started Dec 2023; status: completed.
02
Drugs
oxylanthanum carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT06218290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218290.